{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:31:36Z","timestamp":1765369896552,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002635","name":"Inha University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["202012E0102"],"award-info":[{"award-number":["202012E0102"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2019R1C1C1009359"],"award-info":[{"award-number":["2019R1C1C1009359"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019266","name":"Korea Medical Device Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clcc.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T12:47:58Z","timestamp":1637239678000},"page":"e78-e86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Jeongshim","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woong Sub","family":"Koom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa Kyung","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joong Bae","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Hoon","family":"Beom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Sang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Joon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangpyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-3382","authenticated-orcid":false,"given":"Jee Suk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2021.10.009_bib0001","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2021.10.009_bib0002","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Yachida","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clcc.2021.10.009_bib0003","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2021.10.009_bib0004","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102894","article-title":"The use of radiation therapy for oligoprogressive\/oligopersistent oncogene-driven non small cell lung cancer: State of the art","volume":"148","author":"Franceschini","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/PPO.0000000000000434","article-title":"Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease","volume":"26","author":"Foster","year":"2020","journal-title":"Cancer J"},{"key":"10.1016\/j.clcc.2021.10.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.4489","article-title":"The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0009","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1080\/02841860802662722","article-title":"Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis","volume":"48","author":"Rusthoven","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0010","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1245\/s10434-014-4363-5","article-title":"Incorporation of radiotherapy in the multidisciplinary treatment of isolated retroperitoneal lymph node recurrence from colorectal cancer","volume":"22","author":"Lee","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2021.10.009_bib0011","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijmedinf.2013.02.001","article-title":"Assessment of efficiency and safety of the comprehensive chemotherapy assistance program for ordering oncology medications","volume":"82","author":"Cho","year":"2013","journal-title":"Int J Med Inform"},{"key":"10.1016\/j.clcc.2021.10.009_bib0012","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0013","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.radonc.2018.04.022","article-title":"Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression","volume":"127","author":"Pembroke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0014","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0016","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.euo.2019.08.012","article-title":"Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer","volume":"4","author":"Berghen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13014-020-01730-0","article-title":"Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database","volume":"16","author":"Kroeze","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0018","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1200\/JCO.2020.38.15_suppl.5065","article-title":"A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy","volume":"38","author":"Cheung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0019","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0020","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0021","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2019.08.018","article-title":"Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter","volume":"142","author":"Thompson","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0022","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","article-title":"Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy","volume":"10","author":"Al-Halabi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0023","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","article-title":"Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer","volume":"32","author":"Iyengar","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0024","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.lungcan.2013.05.019","article-title":"EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung","volume":"81","author":"Conforti","year":"2013","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.clcc.2021.10.009_bib0025","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2020.05.004","article-title":"Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer","volume":"4","author":"Deek","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0026","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1186\/s12885-019-6449-8","article-title":"Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer","volume":"19","author":"Kissel","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2021.10.009_bib0027","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10585-019-09976-z","article-title":"Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions","volume":"36","author":"Dell'Acqua","year":"2019","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clcc.2021.10.009_bib0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.02.008","article-title":"Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer","volume":"146","author":"Jethwa","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","article-title":"Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control","volume":"123","author":"Klement","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clcc.2021.10.009_bib0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.radonc.2020.08.012","article-title":"Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy","volume":"151","author":"O'Cathail","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2021.10.009_bib0031","first-page":"440-","article-title":"Stereotactic Radiotherapy for Oligometastasis","volume":"81","author":"Otake","year":"2013","journal-title":"Cancers (Basel)"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002821001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002821001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:52Z","timestamp":1761520132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002821001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1533002821001201"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2021.10.009","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}